{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HIV+in+Adults&page=5", "query": { "condition": "HIV in Adults", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 545, "total_pages": 55, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HIV+in+Adults&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HIV+in+Adults&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T01:34:44.801Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00195312", "title": "Study Evaluating Vaccine in Adults With HIV", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HIV-1 gag DNA (formulated with bupivacaine)", "type": "BIOLOGICAL" }, { "name": "IL-15 DNA (formulated with bupivacaine)", "type": "BIOLOGICAL" }, { "name": "IL-12 DNA (formulated with bupivacaine)", "type": "BIOLOGICAL" }, { "name": "Sodium chloride injection USP (0.9%)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 91, "start_date": "2005-08", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2007-12-05", "last_synced_at": "2026-10-08T01:34:44.801Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00195312" }, { "nct_id": "NCT00001295", "title": "Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "HIV" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "99 Years", "sex": "ALL", "summary": "Up to 99 Years" }, "enrollment_count": 2145, "start_date": "1992-01-29", "completion_date": "2016-08-23", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-08T01:34:44.801Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001295" }, { "nct_id": "NCT02296541", "title": "Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DNA Nat-B env", "type": "BIOLOGICAL" }, { "name": "DNA CON-S env", "type": "BIOLOGICAL" }, { "name": "DNA Mosaic env", "type": "BIOLOGICAL" }, { "name": "MVA-CMDR", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA Nat-B env", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA CON-S env", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA Mosaic env", "type": "BIOLOGICAL" }, { "name": "Placebo for MVA-CMDR", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 105, "start_date": "2014-12", "completion_date": "2020-07-06", "has_results": false, "last_update_posted_date": "2023-04-24", "last_synced_at": "2026-10-08T01:34:44.801Z", "location_count": 6, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296541" }, { "nct_id": "NCT00757783", "title": "Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "ritonavir", "type": "DRUG" }, { "name": "darunavir", "type": "DRUG" }, { "name": "emtricitabine [FTC]/tenofovir [TDF]", "type": "DRUG" }, { "name": "atazanavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 68, "start_date": "2008-10", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2015-12-30", "last_synced_at": "2026-10-08T01:34:44.801Z", "location_count": 15, "location_summary": "Los Angeles, California • Glastonbury, Connecticut • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Glastonbury", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00757783" }, { "nct_id": "NCT03758066", "title": "PlusCare: Mobile Platform to Increase Linkage to Care in Adolescents Living With HIV/AIDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV/AIDS" ], "interventions": [ { "name": "PlusCare", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Dimagi Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "13 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "13 Years to 25 Years" }, "enrollment_count": 65, "start_date": "2019-01-02", "completion_date": "2020-12-31", "has_results": true, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-10-08T01:34:44.801Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03758066" }, { "nct_id": "NCT06343311", "title": "T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-Cell Non-Hodgkin's Lymphoma (NHL)", "Lymphoma, Non-Hodgkins", "Lymphomas Non-Hodgkin's B-Cell", "Non-Hodgkin Lymphoma", "Non-Hodgkin's Lymphoma", "Large B-Cell Lymphoma", "Lymphoma, Non-Hodgkin's, Adult", "Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Relapsed Non-Hodgkin Lymphoma", "Lymphoma, Non-Hodgkin", "HIV Associated Lymphoma", "CNS Lymphoma", "High-grade B-cell Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "EB103", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Estrella Immunopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-06-01", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-08T01:34:44.801Z", "location_count": 5, "location_summary": "Sacramento, California • Cleveland, Ohio • Portland, Oregon + 2 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06343311" }, { "nct_id": "NCT02478632", "title": "Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Subjects do not receive study medication in this study 202094", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2015-06-12", "completion_date": "2018-08-17", "has_results": true, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-08T01:34:44.801Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02478632" }, { "nct_id": "NCT01497899", "title": "Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "E/C/F/TAF Placebo", "type": "DRUG" }, { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "E/C/F/TDF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 279, "start_date": "2011-12-28", "completion_date": "2016-08-22", "has_results": true, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-10-08T01:34:44.801Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01497899" }, { "nct_id": "NCT07390474", "title": "Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "DV201P-RNA", "type": "BIOLOGICAL" }, { "name": "DV202B1-RNA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2026-03-25", "completion_date": "2027-12-14", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-08T01:34:44.801Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Decatur, Georgia • Boston, Massachusetts + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07390474" }, { "nct_id": "NCT03721510", "title": "A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV/AIDS" ], "interventions": [ { "name": "PGT121 + VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "PGT121 + VRC07-523LS + PGDM1400", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "International AIDS Vaccine Initiative", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 19, "start_date": "2018-12-03", "completion_date": "2022-05-02", "has_results": false, "last_update_posted_date": "2022-05-10", "last_synced_at": "2026-10-08T01:34:44.801Z", "location_count": 3, "location_summary": "Orlando, Florida • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03721510" } ] }